MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+1.4%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	8/2/2007 8:20:02 AM
	of 2240

Genmab Regains Rights to HuMax-TAC Genmab A/S (OMX (Stockholm: OMX.ST - news) : GEN) announced today it has regained all rights to the HuMax-TAC (Berlin: TDC.BE - news) (TM) antibody from Merck Serono (Virt-X: SEO.VX - news) following a portfolio review by Merck Serono. Worldwide rights to HuMax-TAC were previously licensed to Merck (MERK.JK - news) Serono in May 2005. Regaining the rights to HuMax-TAC will not influence Genmab's financial guidance for 2007. "Now that we have regained rights to the HuMax-TAC program, Genmab will review the program internally to decide on future plans," said Lisa N. Drakeman, Ph.D.,Chief Executive Officer of Genmab...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next